GlaxoSmithKline PLC ADR Asset Resilience Ratio
GlaxoSmithKline PLC ADR asset resilience ratio. GlaxoSmithKline PLC ADR (GSK) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of GlaxoSmithKline PLC ADR to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of GlaxoSmithKline PLC ADR (1985–2025)
Asset resilience ratio of GlaxoSmithKline PLC ADR from 1985 to 2025. This chart shows how GlaxoSmithKline PLC ADR's Asset Resilience Ratio has changed over time. Read GlaxoSmithKline PLC ADR total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down GlaxoSmithKline PLC ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see GlaxoSmithKline PLC ADR asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $993.96K | 0.0% |
| Total Liquid Assets | $993.96K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: GlaxoSmithKline PLC ADR maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
GlaxoSmithKline PLC ADR Industry Peers by Asset Resilience Ratio
Compare GlaxoSmithKline PLC ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.33% |
|
Novo Nordisk A/S
CO:NOVO-B |
Drug Manufacturers - General | 0.09% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
SANOFI CONS HEALTHC IND L
NSE:SANOFICONR |
Drug Manufacturers - General | 0.07% |
GlaxoSmithKline PLC ADR Asset Resilience Ratio by Year (1985–2025)
GlaxoSmithKline PLC ADR asset resilience ratio by year from 1985 to 2025. The table below shows the annual Asset Resilience Ratio data for GlaxoSmithKline PLC ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.93% | $2.40 Billion | $61.01 Billion | -0.73pp |
| 2024-12-31 | 4.66% | $2.77 Billion | $59.46 Billion | -1.80pp |
| 2023-12-31 | 6.46% | $4.86 Billion | $75.22 Billion | -6.63pp |
| 2022-12-31 | 13.10% | $7.88 Billion | $60.15 Billion | +13.02pp |
| 2021-12-31 | 0.08% | $82.62 Million | $107.14 Billion | -0.02pp |
| 2020-12-31 | 0.10% | $106.62 Million | $109.95 Billion | 0.00pp |
| 2019-12-31 | 0.10% | $104.66 Million | $105.57 Billion | -0.05pp |
| 2018-12-31 | 0.14% | $84.00 Million | $58.07 Billion | +0.01pp |
| 2017-12-31 | 0.14% | $78.00 Million | $56.38 Billion | -0.01pp |
| 2016-12-31 | 0.15% | $89.00 Million | $59.08 Billion | +0.01pp |
| 2015-12-31 | 0.14% | $75.00 Million | $53.45 Billion | -0.03pp |
| 2014-12-31 | 0.17% | $69.00 Million | $40.65 Billion | +0.01pp |
| 2013-12-31 | 0.16% | $66.00 Million | $42.09 Billion | -0.04pp |
| 2012-12-31 | 0.20% | $81.00 Million | $41.48 Billion | -0.25pp |
| 2011-12-31 | 0.45% | $184.00 Million | $41.08 Billion | -0.21pp |
| 2010-12-31 | 0.66% | $277.00 Million | $42.05 Billion | -0.27pp |
| 2009-12-31 | 0.93% | $397.00 Million | $42.86 Billion | -0.07pp |
| 2008-12-31 | 0.99% | $391.00 Million | $39.39 Billion | -2.73pp |
| 2007-12-31 | 3.72% | $1.15 Billion | $31.00 Billion | -0.33pp |
| 2006-12-31 | 4.05% | $1.03 Billion | $25.55 Billion | +0.28pp |
| 2005-12-31 | 3.77% | $1.02 Billion | $27.20 Billion | -2.82pp |
| 2004-12-31 | 6.59% | $1.51 Billion | $22.94 Billion | -3.81pp |
| 2003-12-31 | 10.40% | $2.49 Billion | $23.94 Billion | +4.05pp |
| 2002-12-31 | 6.35% | $1.42 Billion | $22.33 Billion | -0.95pp |
| 2001-12-31 | 7.30% | $1.60 Billion | $21.97 Billion | -3.39pp |
| 2000-12-31 | 10.69% | $2.31 Billion | $21.59 Billion | -6.08pp |
| 1999-12-31 | 16.77% | $1.75 Billion | $10.43 Billion | -0.83pp |
| 1998-12-31 | 17.60% | $1.65 Billion | $9.35 Billion | +0.45pp |
| 1997-12-31 | 17.15% | $1.45 Billion | $8.44 Billion | +5.11pp |
| 1996-12-31 | 12.04% | $1.00 Billion | $8.31 Billion | -0.15pp |
| 1995-12-31 | 12.19% | $1.04 Billion | $8.54 Billion | -22.15pp |
| 1993-12-31 | 34.33% | $2.71 Billion | $7.89 Billion | +1.70pp |
| 1992-12-31 | 32.64% | $2.43 Billion | $7.46 Billion | +2.28pp |
| 1991-12-31 | 30.36% | $1.73 Billion | $5.68 Billion | -6.11pp |
| 1990-12-31 | 36.47% | $2.10 Billion | $5.74 Billion | +6.95pp |
| 1989-12-31 | 29.52% | $1.33 Billion | $4.49 Billion | +8.79pp |
| 1988-12-31 | 20.73% | $719.00 Million | $3.47 Billion | -18.76pp |
| 1987-12-31 | 39.48% | $1.13 Billion | $2.87 Billion | +0.81pp |
| 1986-12-31 | 38.68% | $912.00 Million | $2.36 Billion | +7.78pp |
| 1985-12-31 | 30.89% | $557.00 Million | $1.80 Billion | -- |
About GlaxoSmithKline PLC ADR
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more